Insulin aspart

DB01306ApprovedInvestigationalProtein Based TherapiesBlood Glucose Lowering AgentsInsulin Analog

Insulin aspart is a rapid-acting form of insulin used for glycemic control in type 1 and type 2 diabetes mellitus. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism.

Protein structure of Insulin aspart
Mechanism
Curator reviewed
Primary indication
Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.Curator reviewed · 9 structured indications
Formula / weight
C256H381N65O79S6 · 5825.8 Da
First approval
Canada, 2001 · United States, 2001 · European Union, 2016
Also known as
Aspart · Aspart Insulin · B28-Aspart-Insulin · Insulin aspart protamine · Insulin aspart protamine recombinant
Code names
INA-X14 · NN-1218
Brand names
  • Fiasp
  • Garzulys
  • Insulin Aspart Sanofi
  • Kixelle
  • Merilog
  • Novolog
  • Novolog Mix
  • Novomix
  • Novorapid
  • Novorapid Penfill
  • Ryzodeg
  • +1 moreShow less

Resolves to

What you can answer from here — as of July 17, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
798Drug interactionsStructured to mechanism, not free text
Sign in
148Clinical trialsPhase, status and sponsor resolved per trial
Sign in
9Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
289Marketed productsAcross 10 countries and 19 labellers
Sign in
3ATC codesIncluding every combination product, plus 17 drug categories
Sign in
16+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Insulin aspart, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account